There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Background Breast cancer remains the number 1 lethal malignancy in women. With rising
incidence and decreased mortality, the number of breast cancer survivors has increased …

Approximately 0.5 million people worldwide die from metastatic breast cancer (mBC) every
year. This manuscript provides an overview on the status of mBC in several regions of the …

Introduction The differentiation between acute and chronic pain can be insufficient for
appropriate pain management. The aim of this study was to evaluate the prevalence of the …

Endocrine therapy is currently the main therapeutic approach for estrogen receptor-positive
(ER+) breast cancer, the most frequent subtype of breast cancer in women worldwide. For …

Abstract Cyclin dependent kinase (CDK) 4/6 inhibitors have advanced the treatment of
metastatic breast cancer by targeting the cell cycle machinery, interrupting intracellular and …

Breast cancer (BC) is the most frequently diagnosed malignancy in women worldwide.
Almost 70–80% of cases of BC are curable at the early non-metastatic stage. BC is a …

Cytochrome P450 19A1 (P450 19A1), the aromatase, catalyzes the conversion of
androgens to estrogens through a sequential three-step reaction, generating 19-hydroxy …

Background Breast cancer has, due to its high incidence, the highest mortality of cancer in
women. The most common molecular type of breast cancer is the luminal subtype, which …

It is a challenging task to design target-specific and less toxic non-steroidal aromatase
inhibitors (NSAIs) though the modeling studies for designing anti-aromatase molecules have …